BOD Science Ltd Total Liabilities

Latest as of June 2025: AU$7.75 Million AUD ≈ $5.48 Million USD

BOD Science Ltd total liabilities. Based on the latest financial reports, BOD Science Ltd (BOD) has total liabilities worth AU$7.75 Million AUD (≈ $5.48 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BOD financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of BOD Science Ltd (2016–2025)

Total liabilities of BOD Science Ltd from 2016 to 2025. This chart illustrates how BOD Science Ltd's total liabilities have evolved over time, based on quarterly financial data.

BOD Science Ltd Competitors by Total Liabilities

The table below lists competitors of BOD Science Ltd ranked by their total liabilities.

Company Country Total Liabilities
Real Estate Credit Investments Limited
LSE:RECI
UK GBX117.51 Million
WOODPECKER.CO ZY -10
F:8FG
Germany €5.12 Million
Tarrina Resources Limited
AU:TR8
Australia AU$162.12K
Secure Trust Bank PLC
LSE:STB
UK GBX3.56 Billion
Ridgetech, Inc.
NASDAQ:RDGT
USA $28.25 Million
FIRST CLASS MET. LS-001
F:WN9
Germany €606.72K
Ankit Metal & Power Limited
NSE:ANKITMETAL
India Rs10.32 Billion
Telemasters Holdings Ltd
JSE:TLM
South Africa ZAC15.91 Million

Liability Composition Analysis (2016–2025)

This chart breaks down BOD Science Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is BOD Science Ltd's balance sheet.

Liquidity & Leverage Metrics

BOD Science Ltd Total Liabilities Ratios Explained

BOD Science Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.34 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.50 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 2.98 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BOD Science Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BOD Science Ltd (2016–2025)

The table below shows the annual total liabilities of BOD Science Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-06-30 AU$7.75 Million
≈ $5.48 Million
+1.65%
2024-06-30 AU$7.63 Million
≈ $5.40 Million
+81.24%
2023-06-30 AU$4.21 Million
≈ $2.98 Million
+127.83%
2022-06-30 AU$1.85 Million
≈ $1.31 Million
+9.17%
2021-06-30 AU$1.69 Million
≈ $1.20 Million
-58.81%
2020-06-30 AU$4.11 Million
≈ $2.91 Million
+188.16%
2019-06-30 AU$1.43 Million
≈ $1.01 Million
+17.65%
2018-06-30 AU$1.21 Million
≈ $857.13K
+99.66%
2017-06-30 AU$606.72K
≈ $429.29K
+503.57%
2016-06-30 AU$100.52K
≈ $71.13K
--

About BOD Science Ltd

AU:BOD Australia Drug Manufacturers - Specialty & Generic
Market Cap
$3.01 Million
AU$4.26 Million AUD
Market Cap Rank
#29427 Global
#1639 in Australia
Share Price
AU$0.02
Change (1 day)
+0.00%
52-Week Range
AU$0.02 - AU$0.02
All Time High
AU$0.67
About

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and dis… Read more